In my understanding, ATH needs to make a public announcement before the AAN congress if the posters have either positive or negative information about the efficacy of ATH434. I would expect more information about the primate study. Still, all 3 posters may have non-published info relating to the efficacy of ATH434 despite Stamler's and Claassen's posters not needing price-sensitive data.
Upcoming presentation dates and time at AAN, with preliminary phase 2 timeline, page-102
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $7.879K | 2.590M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 58 | 79758033 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 1157860 | 1 |
View Market Depth
| Last trade - 15.57pm 17/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |